Cheng Du Sheng Nuo Biotec Co. Ltd. A - Asset Resilience Ratio

Latest as of September 2025: 3.51%

Cheng Du Sheng Nuo Biotec Co. Ltd. A (688117) has an Asset Resilience Ratio of 3.51% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥67.00 Million
≈ $9.80 Million USD Cash + Short-term Investments

Total Assets

CN¥1.91 Billion
≈ $279.37 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2024)

This chart shows how Cheng Du Sheng Nuo Biotec Co. Ltd. A's Asset Resilience Ratio has changed over time. See Cheng Du Sheng Nuo Biotec Co. Ltd. A leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Cheng Du Sheng Nuo Biotec Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Cheng Du Sheng Nuo Biotec Co. Ltd. A.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥67.00 Million 3.51%
Total Liquid Assets CN¥67.00 Million 3.51%

Asset Resilience Insights

  • Limited Liquidity: Cheng Du Sheng Nuo Biotec Co. Ltd. A maintains only 3.51% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Cheng Du Sheng Nuo Biotec Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Cheng Du Sheng Nuo Biotec Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
JW Pharmaceutical Corp
KO:001067
Drug Manufacturers - Specialty & Generic 8.17%
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
Drug Manufacturers - Specialty & Generic 0.16%
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
Drug Manufacturers - Specialty & Generic 11.60%
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
Drug Manufacturers - Specialty & Generic 14.80%
Fuan Pharmaceutical Group Co
SHE:300194
Drug Manufacturers - Specialty & Generic 1.34%
DRI Healthcare Trust
TO:DHT-U
Drug Manufacturers - Specialty & Generic 13.91%
Hainan Shuangcheng Pharmaceut
SHE:002693
Drug Manufacturers - Specialty & Generic 1.03%

Annual Asset Resilience Ratio for Cheng Du Sheng Nuo Biotec Co. Ltd. A (2021–2024)

The table below shows the annual Asset Resilience Ratio data for Cheng Du Sheng Nuo Biotec Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 1.22% CN¥20.16 Million
≈ $2.95 Million
CN¥1.65 Billion
≈ $241.14 Million
-2.58pp
2023-12-31 3.80% CN¥50.00 Million
≈ $7.32 Million
CN¥1.32 Billion
≈ $192.53 Million
-17.11pp
2021-12-31 20.91% CN¥200.00 Million
≈ $29.27 Million
CN¥956.62 Million
≈ $139.98 Million
--
pp = percentage points

About Cheng Du Sheng Nuo Biotec Co. Ltd. A

SHG:688117 China Drug Manufacturers - Specialty & Generic
Market Cap
$569.77 Million
CN¥3.89 Billion CNY
Market Cap Rank
#11561 Global
#3265 in China
Share Price
CN¥24.74
Change (1 day)
+0.98%
52-Week Range
CN¥21.44 - CN¥46.10
All Time High
CN¥48.78
About

ChengDu ShengNuo Biotec Co.,Ltd. engages in the research and development, production, sale, and export of peptide drugs. The company offers semaglutide, tirzepatide, retatrutide, cagrilintide, lanreotide, bivalirudin, epitifibatide, liraglutide; icatibant, octreotide, teriparatide, ziconotide, ganirelix, linaclotide, abaloparatide, terlipressin acetate; levosimendane, thymosin alpha, enfuvirtide,… Read more